Last reviewed · How we verify
Treatment-experienced patients- MNDL therapy
MNDL therapy is a treatment regimen for treatment-experienced hepatitis C patients, likely combining antiviral agents to target viral replication and clearance.
MNDL therapy is a treatment regimen for treatment-experienced hepatitis C patients, likely combining antiviral agents to target viral replication and clearance. Used for Treatment-experienced hepatitis C virus (HCV) infection.
At a glance
| Generic name | Treatment-experienced patients- MNDL therapy |
|---|---|
| Sponsor | National Liver Institute, Egypt |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
MNDL appears to be a multi-drug regimen developed by the National Liver Institute in Egypt for patients who have failed prior hepatitis C treatments. The exact composition and mechanism are not clearly defined in available literature, but such regimens typically employ direct-acting antivirals (DAAs) targeting viral protease, polymerase, or NS5A proteins to inhibit viral replication and achieve sustained virologic response.
Approved indications
- Treatment-experienced hepatitis C virus (HCV) infection
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: